Company intelligence / Profile preview

inRegen

Ownership: Private
Development stage: Phase 3

Overview

inRegen's primary program, ReACT, is an autologous cell therapy intended to restore kidney function in chronic kidney disease by expanding and re-implanting a patient's own progenitor cells; it was in clinical development at the time of the company's 2019 acquisition, but public clinical data on efficacy is limited.

Therapeutic areas: NephrologyMen's HealthCardiovascular
Modalities: Cell therapyAutologous cell therapy
Industry: Biotech

Drug pipeline

1 asset

REACT

Phase 3

Indications: Chronic kidney disease, Diabetic kidney disease

Beyond the preview

Go deeper on inRegen.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on inRegen.

Explore the full profile